EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

Mônica R Gadelha iD, Alessandra Casagrande, Christian J Strasburger, Martin Bidlingmaier iD, Peter J Snyder, Mirtha A Guitelman, Cesar L Boguszewski, Michael Buchfelder, Ilan Shimon, Gerald Raverot iD, Miklós Tóth, Emese Mezősi und 7 weitere

The Journal of Clinical Endocrinology & Metabolism · 18.12.2024 · 110 (1) · 228-237

DOI: 10.1210/clinem/dgae385 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.06.2024. Verfasst von Mônica R Gadelha und 18 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do …. Hauptthemen laut MEDLINE: Acromegaly, Receptors, Somatostatin, Octreotide, Somatostatin. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crinetics Pharmaceuticals, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly.

Objective

To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs).

Methods

This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had IGF-I ≤1.0 times the upper limit of normal (×ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected SRLs and randomized to receive paltusotine or placebo orally for 36 weeks. The primary endpoint was proportion of patients maintaining IGF-I ≤1.0× ULN. Secondary endpoints were change in IGF-I level, change in Acromegaly Symptom Diary score, and maintenance of mean 5-sample GH <1.0 ng/mL.

Results

The primary endpoint was met: 83.3% (25/30) of patients receiving paltusotine and 3.6% (1/28) receiving placebo maintained IGF-I ≤1.0× ULN (odds ratio, 126.53; 95% CI, 13.73->999.99; P < .0001). Paltusotine was also superior to placebo for all secondary endpoints: mean (± SE) change in IGF-I of 0.04 ± 0.09× ULN vs 0.83 ± 0.1× ULN (P < .0001); mean (± SE) change in Acromegaly Symptom Diary score of −0.6 ± 1.5 vs 4.6 ± 1.6 (P = .02); mean GH maintained at <1.0 ng/mL in 20/23 (87.0%) vs 5/18 (27.8%) patients (odds ratio, 16.61; 95% CI, 2.86-181.36; P = .0003). The most common adverse events were acromegaly symptoms and gastrointestinal effects characteristic of SRLs.

Conclusion

Replacement of injected SRLs by once-daily oral paltusotine was effective in maintaining both biochemical and symptom control in patients with acromegaly and was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyReceptors, SomatostatinOctreotideSomatostatinHumansMaleFemaleMiddle AgedAdultDouble-Blind MethodAdministration, OralTreatment OutcomeAgedInsulin-Like Growth Factor IPeptides, CyclicLigandsHuman Growth Hormone

Stichwörter der Autor:innen

IGF-Iacromegalyclinical trialpaltusotinesomatostatinsomatostatin receptor 2

Substanzen

Receptors, SomatostatinOctreotideSomatostatinInsulin-Like Growth Factor IlanreotidePeptides, CyclicLigandsHuman Growth Hormone

Autor:innen und Institutionen

  • Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro CEP 21941-913, Brazil.
  • Crinetics Pharmaceuticals, Inc., San Diego, CA 92121, USA.
  • Department of Medicine for Endocrinology and Metabolic Disorders, Charité Universitaetsmedizin, Berlin 10117, Germany.
  • Neuroendocrine Research Group, Department of Internal Medicine, Ludwig-Maximilians University, Munich 80336, Germany.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • División Endocrinología, Hospital Carlos G. Durand, Buenos Aires 1405, Argentina.

ORCID-Profile: Mônica R Gadelha, Martin Bidlingmaier, Gerald Raverot, Alan Krasner

Förderung

  • Crinetics Pharmaceuticals, Inc

Zitieren

APA

Gadelha, M. R., Casagrande, A., Strasburger, C. J., Bidlingmaier, M., Snyder, P. J., Guitelman, M. A., Boguszewski, C. L., Buchfelder, M., Shimon, I., Raverot, G., Tóth, M., Mezősi, E., Doknic, M., Fan, X., Clemmons, D., Trainer, P. J., Struthers, R. S., Krasner, A., & Biller, B. M. K. (2024). Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. The Journal of Clinical Endocrinology & Metabolism, 110(1), 228-237. https://doi.org/10.1210/clinem/dgae385

Vancouver

Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, et al. Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. The Journal of Clinical Endocrinology & Metabolism. 2024;110(1):228-237. doi:10.1210/clinem/dgae385

BibTeX
@article{Gadelha2024,
  author = {Gadelha, Mônica R and Casagrande, Alessandra and Strasburger, Christian J and Bidlingmaier, Martin and Snyder, Peter J and Guitelman, Mirtha A and Boguszewski, Cesar L and Buchfelder, Michael and Shimon, Ilan and Raverot, Gerald and Tóth, Miklós and Mezősi, Emese and Doknic, Mirjana and Fan, Xiaolin and Clemmons, David and Trainer, Peter J and Struthers, R Scott and Krasner, Alan and Biller, Beverly M K},
  title = {Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {110},
  number = {1},
  pages = {228--237},
  doi = {10.1210/clinem/dgae385}
}
Kostenlos starten →